DBV Technologies price target raised to $5 from $4 at JMP Securities

JMP Securities raised the firm’s price target on DBV Technologies to $5 from $4 and keeps an Outperform rating on the shares. The Phase 3 VITESSE trial remains on track to complete enrollment this quarter while DBV continues to make progress in getting the COMFORT Toddlers safety study started, the analyst tells investors in a research note. The firm likes that the Phase 3 trial is running on schedule, giving line of sight to data likely in 4Q25 and continues to like the opportunity for Viaskin Peanut in both age groups as JMP thinks an agreement from FDA on the protocols will substantially derisk the regulatory path.